N-[4-(4-isopropyl-piperazin-1-yl)-phenyl]-N'-methyl-pyrimidine-4,6-diamine | 872511-75-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[4-(4-isopropyl-piperazin-1-yl)-phenyl]-N'-methyl-pyrimidine-4,6-diamine
• 英文别名: 6-N-methyl-4-N-[4-(4-propan-2-ylpiperazin-1-yl)phenyl]pyrimidine-4,6-diamine
• CAS: 872511-75-6
• 化学式: C₁₈H₂₆N₆
• 分子量: 326.445
• InChiKey: JDLXAINAUMRRRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  56.3
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES PYRIMIDINES UREE EN TANT QU'INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2006000420A1

  公开（公告）日：2006-01-05

  The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

  该发明涉及式(I)的化合物，其中取代基X1、R1、R2、R3和R4的含义如所述并解释在该发明的描述中，以及制备这些化合物的方法，含有相同化合物的药物组合物，可选择与一个或多个其他药用活性化合物结合使用，用于治疗对蛋白激酶活性抑制有反应的疾病，并且用于治疗此类疾病的方法。
• Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors
  申请人：Bold Guido

  公开号：US20080312248A1

  公开（公告）日：2008-12-18

  The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

  本发明涉及公式IA的杂环芳基基脲化合物，其中基团和符号的含义如本文所定义，这些化合物在蛋白激酶依赖性疾病的治疗中的使用；含有上述杂环芳基基脲化合物的制药制剂；制备这些新化合物的方法以及使用这些杂环芳基基脲化合物的治疗方法。
• Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors
  申请人：Novartis AG

  公开号：US20130030171A1

  公开（公告）日：2013-01-31

  The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

  本发明涉及式子IA的杂环芳基芳基脲，其中基团和符号的含义在此定义，这些化合物在蛋白激酶依赖性疾病的治疗中的使用；制备包括所述杂环芳基芳基脲的药物制剂；制造这种新型化合物的过程以及包括使用这种杂环芳基芳基脲的治疗方法。
• COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  申请人：DING Qiang

  公开号：US20130012476A1

  公开（公告）日：2013-01-10

  The invention relates to compounds of formula (I) wherein the substituents X 1 , R 1 , R 2 , R 3 and R 4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

  本发明涉及公式（I）的化合物，其中取代基X1、R1、R2、R3和R4的含义如发明说明中所述和解释的那样，以及制备这些化合物的方法、包含它们的药物组合物，其可选择与一个或多个其他药理活性化合物结合使用，用于治疗对蛋白激酶活性抑制有反应的疾病，以及用于治疗这种疾病的方法。
• Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Ding Qiang

  公开号：US20090137804A1

  公开（公告）日：2009-05-28

  The invention relates to compounds of formula (I) wherein the substituents X 1 , R 1 , R 2 , R 3 and R 4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.

  本发明涉及公式（I）化合物，其中取代基X1，R1，R2，R3和R4的含义如本发明说明书所述和解释的那样，以及制备这些化合物的过程，包含它们的药物组合物，可选择与一种或多种其他药物活性化合物联合使用以治疗对蛋白激酶活性抑制有反应的疾病，以及治疗这种疾病的方法。